Search results
Results from the WOW.Com Content Network
An Hsp90 inhibitor is a substance that inhibits that activity of the Hsp90 heat shock protein. Since Hsp90 stabilizes a variety of proteins required for survival of cancer cells, these substances may have therapeutic benefit in the treatment of various types of malignancies. [ 2 ]
Tyrosine kinase inhibitor (TKI) with selective activity against RET, VEGFR-2 and EGFR: Medullary thyroid cancer. Diarrhoea, hypertension, QT interval prolongation, depression, electrolyte anomalies, hypothyroidism and GI perforation (uncommon). 2.3 mTOR inhibitors: Everolimus: PO: mTOR inhibitor.
Intense heating will cause denaturation and coagulation of cellular proteins, rapidly killing cells within a tumour. More prolonged moderate heating to temperatures just a few degrees above normal (39.5 °C) can cause more subtle changes. A mild heat treatment combined with other stresses can cause cell death by apoptosis.
Cancer treatments are a wide range of treatments available for the many different types of cancer, with each cancer type needing its own specific treatment. [1] Treatments can include surgery, chemotherapy, radiation therapy, hormonal therapy, targeted therapy including small-molecule drugs or monoclonal antibodies, [2] and PARP inhibitors such as olaparib. [3]
Larotrectinib, sold under the brand name Vitrakvi, is a medication for the treatment of cancer. [ 1 ] [ 5 ] [ 7 ] It is an inhibitor of tropomyosin kinase receptors TrkA , TrkB , and TrkC . [ 8 ] [ 9 ] [ 10 ] It was discovered by Array BioPharma and licensed to Loxo Oncology in 2013.
Patient is undergoing local hyperthermia treatment for head and neck cancer. Local hyperthermia heats a very small area and is typically used for cancers near or on the skin or near natural openings in the body (e.g., the mouth). [6] In some instances, the goal is to kill the tumor by heating it, without damaging anything else.
Savolitinib is an experimental small molecule inhibitor of c-Met. It is being investigated for the treatment of cancer by AstraZeneca. [1] It is in phase II clinical trials for adenocarcinoma, non-small cell lung cancer, and renal cell carcinoma. [2] It has been given conditional approval for these indication in China. [3]
Cobimetinib, sold under the brand name Cotellic, is an anti-cancer medication used to treat melanoma and histiocytic neoplasms. [2] [8] Cobimetinib is a MEK inhibitor. [2] ...